20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Castle Biosciences Inc (CSTL) operates in the DIAGNOSTICS & RESEARCH industry and is headquartered in Friendswood, United States with about 1,002 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, CSTL reported $344M in revenue and ($24M) in net income.
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma.
Interactive charts & full statements → Open the CSTL valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $357M | $344M | $332M | $220M | $137M | $94M | $63M | $52M | $23M | $14M |
| Gross Profit | $276M | $273M | $272M | $175M | $105M | $78M | $53M | $45M | $17M | $9M |
| Gross Margin % | 77.3% | 79.4% | 81.9% | 79.5% | 76.6% | 83.2% | 84.5% | 85.9% | 76.8% | 64.2% |
| Operating Income (EBIT) | ($32M) | ($43M) | $9M | ($68M) | ($73M) | ($40M) | ($7M) | $7M | ($4M) | ($11M) |
| Operating Margin % | -9.0% | -12.4% | 2.6% | -30.9% | -53.2% | -42.6% | -10.4% | 14.1% | -16.8% | -79.2% |
| Net Income | ($19M) | ($24M) | $18M | ($57M) | ($67M) | ($31M) | ($10M) | $5M | ($6M) | ($12M) |
| Net Margin % | -5.4% | -7.0% | 5.5% | -26.2% | -49.0% | -33.3% | -16.4% | 10.2% | -27.9% | -89.9% |
| EBITDA | ($3M) | $11M | $38M | ($45M) | ($58M) | ($37M) | ($7M) | $10M | ($4M) | ($10M) |
| Earnings Per Share (EPS) | $-0.65 | $-0.83 | $0.62 | $-2.14 | $-2.58 | $-1.24 | $-0.54 | $0.61 | $-0.60 | $-1.26 |
| Shares Outstanding (M) | 30M | 29M | 29M | 27M | 26M | 25M | 19M | 9M | 11M | 10M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $104M | $84M | $87M | $83M | $86M | $88M | $86M | $86M |
| Gross Profit | $80M | $63M | $69M | $64M | $69M | $72M | $70M | $70M |
| Gross Margin % | 77.1% | 75.5% | 79.0% | 77.5% | 79.5% | 81.4% | 81.2% | 81.8% |
| Operating Income (EBIT) | ($3M) | ($18M) | ($4M) | ($7M) | ($4M) | ($28M) | $4M | $5M |
| Operating Margin % | -3.0% | -22.0% | -4.4% | -8.2% | -4.9% | -31.7% | 4.7% | 5.9% |
| Net Income | ($2M) | ($15M) | ($2M) | ($1M) | $5M | ($26M) | $10M | $2M |
| Net Margin % | -2.0% | -17.3% | -2.7% | -0.6% | 5.2% | -29.4% | 11.1% | 2.6% |
| EBITDA | $3M | ($10M) | $1M | $3M | $3M | $4M | $14M | $12M |
| Earnings Per Share (EPS) | $-0.07 | $-0.49 | $-0.08 | $-0.02 | $0.15 | $-0.90 | $0.32 | $0.08 |
| Shares Outstanding (M) | 30M | 30M | 29M | 29M | 30M | 29M | 30M | 29M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $43M | $64M | $65M | ($6M) | ($42M) | ($19M) | $10M | $7M | ($12M) | ($12M) |
| Capital Expenditures (CapEx) | $43M | $36M | $28M | $14M | $6M | $3M | $5M | $1M | $0M | $0M |
| Free Cash Flow (FCF) | $0M | $28M | $37M | ($19M) | ($47M) | ($22M) | $5M | $6M | ($13M) | ($13M) |
| FCF Margin % | -0.1% | 8.2% | 11.0% | -8.8% | -34.5% | -23.9% | 8.2% | 11.7% | -55.2% | -92.5% |
| Dividends Paid | — | — | — | — | $2M | $3M | — | — | $0M | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $15M | ($22M) | $27M | $23M | $21M | ($6M) | $24M | $23M |
| Capital Expenditures (CapEx) | $9M | $12M | $7M | $15M | $9M | $5M | $8M | $6M |
| Free Cash Flow (FCF) | $7M | ($35M) | $20M | $8M | $12M | ($11M) | $17M | $17M |
| FCF Margin % | 6.3% | -41.3% | 22.7% | 9.4% | 13.4% | -12.2% | 19.5% | 19.8% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $561M | $579M | $531M | $453M | $447M | $463M | $439M | $120M | $22M | $10M |
| Cash & Cash Equivalents | $62M | $117M | $120M | $99M | $123M | $330M | $410M | $99M | $4M | $1M |
| Total Liabilities | $91M | $108M | $75M | $62M | $48M | $51M | $24M | $35M | $32M | $24M |
| Total Debt (Short + Long-Term) | $11M | $11M | $12M | $1M | $2M | $1M | $6M | $25M | $24M | $19M |
| Total Shareholders' Equity | $470M | $471M | $456M | $391M | $399M | $412M | $416M | $85M | ($10M) | ($14M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CSTL viewer.
About TickerBase · Data methodology & sources · Privacy · Terms